Face peeling side effects7/14/2023 Serious side effects of AcitretinĪlong with its needed effects, acitretin may cause some unwanted effects. Mild and reversible, severe, and fatal cases of hepatoxicity have been reported. Acitretin has also been associated with severe hepatotoxicity. All patients must receive the medication guide each time acitretin is dispensed. Men and women must avoid donation of blood during and for at least 3 years following acitretin therapy. The Pregnancy Prevention Actively Required During and After Treatment (Do Your PART) program requirements are available at or 1-88. John's wort during hormonal contraception and signed patient agreement/informed consent form, which includes warning to refrain from consumption of ethanol or ethanol-containing beverages during and for 2 months after treatment discontinuation and avoidance of pregnancy at start of treatment, during, and for at least 3 years after treatment discontinuation. Acitretin is contraindicated in women of childbearing potential unless all of the following criteria are met: 1) two negative urine or serum pregnancy tests (sensitivity at least 25 milli-international units/mL) prior to initiation the first test is a screen test, the second test is a confirmation test done during first 5 days of menstrual period before therapy initiation or done at least 11 days after unprotected sex in amenorrhea patients initiate treatment within 7 days of second negative pregnancy test prescription for acitretin is limited to a 1 month supply 2) pregnancy test must be repeated every month during treatment with a sensitivity of at least 25 milli-international units/mL and test result must be negative before receiving a prescription for the month after discontinuing therapy, a pregnancy test must be repeated every 3 months for at least 3 years 3) commitment to use 2 effective forms of contraception (except the minipill) simultaneously for at least 1 month prior to initiation, during, and for at least 3 years following cessation of therapy unless reproductive status is posthysterectomy or postmenopausal 4) monthly counseling by the prescriber during therapy and every 3 months for at least 3 years following therapy discontinuation about contraception and behaviors associated with an increased risk of pregnancy. Use in women should be reserved for non-pregnant patients with severe psoriasis that did not respond to alternative treatments or when alternative treatments are contraindicated. Acitretin, the active metabolite of etretinate, is teratogenic and major fetal abnormalities have been reported during and after treatment completion.
0 Comments
Leave a Reply. |